## Erin L Winstanley

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8890439/publications.pdf

Version: 2024-02-01

304368 264894 1,905 54 22 42 citations h-index g-index papers 55 55 55 2925 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Polysubstance Use, Mood Disorders, and Chronic Conditions With Anxiety in Opioid Patients. Western Journal of Nursing Research, 2022, 44, 1088-1099.	0.6	4
2	Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale. Journal of Affective Disorders, 2022, 297, 148-155.	2.0	1
3	Distinguishing clinical factors associated with unintentional overdose, suicidal ideation, and attempted suicide among opioid use disorder in-patients. Journal of Psychiatric Research, 2022, 153, 245-253.	1.5	4
4	Using digital technologies in clinical trials: Current and future applications. Contemporary Clinical Trials, 2021, 100, 106219.	0.8	28
5	OD: Naloxone and the Politics of Overdose. NancyCampbellBoston, MA, USA: MIT Press; 2020 ISBN: 9780262043663. Addiction, 2021, 116, 209-210.	1.7	О
6	Hepatitis C virus infection and polysubstance use among young adult people who inject drugs in a rural county of New Mexico. Drug and Alcohol Dependence, 2021, 220, 108527.	1.6	10
7	Assessment of Gabapentin Misuse using Prescription Drug Monitoring Program Data. Substance Abuse, 2021, 42, 454-459.	1.1	2
8	High prevalence of co-occurring substance use in individuals with opioid use disorder. Addictive Behaviors, 2021, 114, 106752.	1.7	19
9	Neurocognitive impairments and brain abnormalities resulting from opioid-related overdoses: A systematic review. Drug and Alcohol Dependence, 2021, 226, 108838.	1.6	15
10	Rapid Transition of Individual and Group-based Behavioral Outpatient Visits to Telepsychiatry in Response to COVID-19. Journal of Addiction Medicine, 2021, 15, 263-265.	1.4	1
11	West Virginia's model of buprenorphine expansion: Preliminary results. Journal of Substance Abuse Treatment, 2020, 108, 40-47.	1.5	27
12	Concurrent Alcohol and Opioid Use Among Harm Reduction Clients. Addictive Behaviors, 2020, 100, 106027.	1.7	10
13	Feasibility and acceptability of safety screening among patients receiving addiction treatment. Journal of Substance Abuse Treatment, 2020, 117, 108092.	1.5	3
14	Impact of naloxone education for patients receiving buprenorphine-containing prescriptions indicated for opioid use disorder at an independent community pharmacy. Journal of the American Pharmacists Association: JAPhA, 2020, 60, e205-e214.	0.7	2
15	The Bell Tolls for Thee & Thine: Compassion Fatigue & the Overdose Epidemic. International Journal of Drug Policy, 2020, 85, 102796.	1.6	29
16	Something to despair: Gender differences in adverse childhood experiences among rural patients. Journal of Substance Abuse Treatment, 2020, 116, 108056.	1.5	16
17	Long-term treatment retention in West Virginia's comprehensive opioid addiction treatment (COAT) program. Journal of the Neurological Sciences, 2020, 411, 116712.	0.3	13
18	Experiences and opinions of health professional students participating in an opioid use disorder educational event. Mental Health Clinician, 2020, 10, 49-54.	0.5	3

#	Article	IF	CITATIONS
19	The Impact of the Opioid Epidemic on Children and Adolescents. Clinical Therapeutics, 2019, 41, 1655-1662.	1.1	57
20	The impact of rural classification systems on a comparison of risky drug-related behaviors in Kentucky and Ohio counties. Journal of Human Behavior in the Social Environment, 2019, 29, 301-307.	1.1	1
21	Emergency Physicians' Perception of Barriers and Facilitators for Adopting an Opioid Prescribing Guideline in Ohio: A Qualitative Interview Study. Journal of Emergency Medicine, 2019, 56, 15-22.	0.3	10
22	Statewide cross-sectional survey of emergency departments' adoption and implementation of the Ohio opioid prescribing guidelines and opioid prescribing practices. BMJ Open, 2018, 8, e020477.	0.8	3
23	Mandatory review of a prescription drug monitoring program and impact on opioid and benzodiazepine dispensing. Drug and Alcohol Dependence, 2018, 188, 169-174.	1.6	72
24	The Promise of Technology-Based Services for Addiction Treatment Clients Residing in Nonurban Areas. Journal of Studies on Alcohol and Drugs, 2018, 79, 503-504.	0.6	3
25	Strategies and policies to address the opioid epidemic: A case study of Ohio. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S148-S153.	0.7	54
26	Inpatient Experiences with MyChart Bedside. Telemedicine Journal and E-Health, 2017, 23, 691-693.	1.6	24
27	The development and feasibility of a pharmacy-delivered opioid intervention in the emergency department. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S87-S91.	0.7	13
28	Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain. Journal of Addictive Diseases, 2016, 35, 42-51.	0.8	55
29	Assessing Fidelity of a Communityâ€Based Opioid Overdose Prevention Program: Modification of the Fidelity Checklist. Journal of Nursing Scholarship, 2016, 48, 371-377.	1.1	5
30	Tangledâ€up and blue: releasing the regulatory chokehold on takeâ€home naloxone. Addiction, 2016, 111, 583-584.	1.7	4
31	Emergency Department Prescription Opioids as an Initial Exposure Preceding Addiction. Annals of Emergency Medicine, 2016, 68, 202-208.	0.3	145
32	Barriers to Implementation of Opioid Overdose Prevention Programs in Ohio. Substance Abuse, 2016, 37, 42-46.	1.1	53
33	Implementation of an inpatient opioid overdose prevention program. Addictive Behaviors, 2016, 53, 141-145.	1.7	0
34	Response to "Quality Assessment Errors and Study Misclassification Threaten Systematic Review Validity. Journal of Addiction Medicine, 2015, 9, 503-504.	1.4	9
35	Using e-technologies in clinical trials. Contemporary Clinical Trials, 2015, 45, 41-54.	0.8	124
36	Improving Treatment for Opioid Dependence: A Perspective From the Ohio Valley Node of the NIDA Clinical Trials Network. Progress in Community Health Partnerships: Research, Education, and Action, 2014, 8, 99-107.	0.2	3

#	Article	IF	Citations
37	Development and Implementation of an Opioid Overdose Prevention Program Within a Preexisting Substance Use Disorders Treatment Center. Journal of Addiction Medicine, 2014, 8, 164-169.	1.4	5
38	A Systematic Review of Community Opioid Overdose Prevention and Naloxone Distribution Programs. Journal of Addiction Medicine, 2014, 8, 153-163.	1.4	352
39	Topiramate for cocaine dependence during methadone maintenance treatment: A randomized controlled trial. Drug and Alcohol Dependence, 2014, 140, 92-100.	1.6	43
40	Moving Beyond Misuse and Diversion: The Urgent Need to Consider the Role of latrogenic Addiction in the Current Opioid Epidemic. American Journal of Public Health, 2014, 104, 2023-2029.	1.5	79
41	Adolescent Substance Abuse and Mental Health: Problem Co-Occurrence and Access to Services. Journal of Child and Adolescent Substance Abuse, 2012, 21, 310-322.	0.5	24
42	A Randomized, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain. Journal of Clinical Psychopharmacology, 2012, 32, 165-172.	0.7	28
43	Prescription Drug Abuse as a Public Health Problem in Ohio: A Case Report. Public Health Nursing, 2012, 29, 553-562.	0.7	13
44	The potential impact of recruitment method on sample characteristics and treatment outcomes in a psychosocial trial for women with co-occurring substance use disorder and PTSD. Drug and Alcohol Dependence, 2012, 120, 225-228.	1.6	17
45	Duloxetine in the treatment of binge eating disorder with depressive disorders: A placeboâ€controlled trial. International Journal of Eating Disorders, 2012, 45, 281-289.	2.1	65
46	A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. Journal of Substance Abuse Treatment, 2011, 40, 255-264.	1.5	40
47	A randomized, placebo-controlled study of adjunctive ramelteon in ambulatory bipolar I disorder with manic symptoms and sleep disturbance. International Clinical Psychopharmacology, 2011, 26, 48-53.	0.9	61
48	Sodium oxybate in the treatment of binge eating disorder: An openâ€label, prospective study. International Journal of Eating Disorders, 2011, 44, 262-268.	2.1	27
49	Acamprosate in the treatment of binge eating disorder: A placeboâ€controlled trial. International Journal of Eating Disorders, 2011, 44, 81-90.	2.1	50
50	Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania. Journal of Affective Disorders, 2010, 124, 157-163.	2.0	31
51	Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary caseâ€series and feasibility. Addiction, 2010, 105, 1669-1676.	1.7	80
52	The world of drinking: national alcohol control experiences in 18 countries. Addiction, 2008, 103, 721-725.	1.7	8
53	The association of self-reported neighborhood disorganization and social capital with adolescent alcohol and drug use, dependence, and access to treatment. Drug and Alcohol Dependence, 2008, 92, 173-182.	1.6	148
54	Drug abuse and HIV/AIDS: international research lessons and imperatives. Drug and Alcohol Dependence, 2006, 82, S1-S5.	1.6	12